India’s Biocon Moves Forward With Oral Insulin After Encouraging Phase II Results
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - In what is seen as a significant development for the company, Indian biotechnology firm Biocon presented encouraging Phase II data on its experimental oral insulin drug coded IN-105 at the European Association for the Study of Diabetes meeting being held at Rome
You may also be interested in...
Biocon Files IND For Oral Insulin In U.S.; Launch In India Likely In 2011
MUMBAI - Amidst a row over the safety and absorption profile of inhaled insulins, Biocon - which steadily advanced its orally-delivered insulin IN-105 into Phase III trials in India - has now filed an investigational new drug application with U.S. FDA
Biocon Files IND For Oral Insulin In U.S.; Launch In India Likely In 2011
MUMBAI - Amidst a row over the safety and absorption profile of inhaled insulins, Biocon - which steadily advanced its orally-delivered insulin IN-105 into Phase III trials in India - has now filed an investigational new drug application with U.S. FDA
India’s Biocon Breaks Into Global Top 10 Biotech List
MUMBAI - Indian biotech firm Biocon has emerged as the seventh largest employer among the top global biotech companies, according to a survey released by Med Ad News